BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 22370627)

  • 1. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.
    Chen X; Sun L; Mao Y; Zhu S; Wu J; Huang O; Li Y; Chen W; Wang J; Yuan Y; Fei X; Jin X; Shen K
    BMC Cancer; 2013 Aug; 13():390. PubMed ID: 23957561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
    Wang N; Wang B; Wang Y; Hu J
    Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
    Aurilio G; Disalvatore D; Pruneri G; Bagnardi V; Viale G; Curigliano G; Adamoli L; Munzone E; Sciandivasci A; De Vita F; Goldhirsch A; Nolè F
    Eur J Cancer; 2014 Jan; 50(2):277-89. PubMed ID: 24269135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment accuracy of core needle biopsy for hormone receptors in breast cancer: a meta-analysis.
    Li S; Yang X; Zhang Y; Fan L; Zhang F; Chen L; Zhou Y; Chen X; Jiang J
    Breast Cancer Res Treat; 2012 Sep; 135(2):325-34. PubMed ID: 22527109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
    Lorgis V; Algros MP; Villanueva C; Chaigneau L; Thierry-Vuillemin A; Nguyen T; Demarchi M; Bazan F; Sautiere JL; Maisonnette-Lescot Y; Ringenbach F; Bontemps P; Pivot X
    Breast; 2011 Jun; 20(3):284-7. PubMed ID: 21288720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy.
    Khoury T; Zakharia Y; Tan W; Kulkarni S; Liu W; Zhang S; Wilding GE; Edge S
    Breast J; 2011; 17(2):180-6. PubMed ID: 21306471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?
    Greer LT; Rosman M; Mylander WC; Hooke J; Kovatich A; Sawyer K; Buras RR; Shriver CD; Tafra L
    J Am Coll Surg; 2013 Feb; 216(2):239-51. PubMed ID: 23141136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of touch imprint cytology of core needle biopsy and section histopathology in breast cancer diagnosis].
    Zhang ZH; Zhao LL; Guo HQ; Zheng S; Zhang BL; Xu XZ; Pan QJ; Zhang BN
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):921-6. PubMed ID: 21223801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
    Arnedos M; Nerurkar A; Osin P; A'Hern R; Smith IE; Dowsett M
    Ann Oncol; 2009 Dec; 20(12):1948-52. PubMed ID: 19570962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
    BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status].
    Hirano A; Shimizu T; Kamimura M; Ogura K; Kim N; Setoguchi Y; Okubo F; Kinoshita J; Ogawa K; Fujibayashi M
    Gan To Kagaku Ryoho; 2011 May; 38(5):771-6. PubMed ID: 21566435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.
    Zeng J; Piscuoglio S; Aggarwal G; Magda J; Friedlander MA; Murray M; Akram M; Reis-Filho JS; Weigelt B; Edelweiss M
    Cancer Cytopathol; 2020 Feb; 128(2):133-145. PubMed ID: 31883437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.